0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > BTLA

BTLA

Brief Information

Name:B- and T-lymphocyte attenuator
Target Synonym:BTLA,B- and T-lymphocyte attenuator,B- and T-lymphocyte-associated protein,B And T Lymphocyte Associated,CD272 Antigen,BTLA1,CD272
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Synonym Name

BTLA,CD272

Background

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tifcemalimab TAB-004; JS-004 Phase 3 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma; Lung Neoplasms; Melanoma; Neoplasm Metastasis Details
ANB-032 ANB-032 Phase 2 Clinical Anaptysbio Inc Inflammation; Dermatitis, Atopic; Eczema Details
Venanprubart LY-3361237 Phase 2 Clinical Sanford-Burnham Medical Research Institute, Eli Lilly And Company Sjogren's Syndrome; Lupus Erythematosus, Systemic; Psoriasis Details
MB-272 MB272; GS-0272 Phase 1 Clinical University Of Oxford Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic Details
HFB-200603 HFB-200603 Phase 1 Clinical HiFiBiO Therapeutics Carcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Tifcemalimab TAB-004; JS-004 Phase 3 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma; Lung Neoplasms; Melanoma; Neoplasm Metastasis Details
ANB-032 ANB-032 Phase 2 Clinical Anaptysbio Inc Inflammation; Dermatitis, Atopic; Eczema Details
Venanprubart LY-3361237 Phase 2 Clinical Sanford-Burnham Medical Research Institute, Eli Lilly And Company Sjogren's Syndrome; Lupus Erythematosus, Systemic; Psoriasis Details
MB-272 MB272; GS-0272 Phase 1 Clinical University Of Oxford Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic Details
HFB-200603 HFB-200603 Phase 1 Clinical HiFiBiO Therapeutics Carcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop

Laisser un message